The FDA just approved a daily pill that doubles the survival time for patients. It’s a historic shift in treating one of the deadliest malignancies. On August 26, 2026, the U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a first-in-class daily pill for adult patients with metastatic pancreatic adenocarcinoma who have previously undergone chemotherapy. Developed by Revolution Medicines, the drug works by targeting the RAS protein, a mutated driver found in over 90% of pancreatic tumors. Historically, pancreatic cancer has been notoriously difficult to treat due to late-stage detection and resistance to standard therapies, leaving patients with exceptionally low survival rates. The approval of Rasonque, which received expedited Priority Review and Breakthrough Therapy designations, represents a monumental leap forward in oncology. The approval is supported by the landmark Phase 3 RASolute 302 trial involving 500 patients. Results published in the New England Journal of Medicine revealed that those taking Rasonque achieved a median overall survival of 13.2 months, compared to just 6.7 months for those receiving standard chemotherapy, and experienced significantly fewer severe side effects. While the drug's high market price of nearly $500,000 annually raises critical questions regarding insurance coverage and global accessibility, the medical community celebrates this milestone as a long-awaited turning point that transforms a historically untreatable disease into a manageable condition. source: Iacobucci, G. (2026). Pancreatic cancer: US approves “breakthrough” drug that may double survival time. The BMJ, 394, e100698.